

## PRIOR AUTHORIZATION POLICY

**POLICY:** Oncology (Other) – Valrubicin Products Prior Authorization Policy

- Valstar® (valrubicin intravesical solution– Endo, generic)

**REVIEW DATE:** 11/30/2022

---

### OVERVIEW

Valrubicin, an anthracycline topoisomerase inhibitor, is indicated for intravesical therapy of BCG-refractory **carcinoma *in situ* (CIS) of the urinary bladder** in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.<sup>1</sup>

### Guidelines

The National Comprehensive Cancer Network guidelines for **bladder cancer** (version 2.2022 – May 20, 2022) recommend intravesical valrubicin in the event of a Bacillus Calmette-Guerin (BCG) shortage and for BCG-refractory carcinoma *in situ* (Tis) disease as either initial therapy if high risk and BCG unresponsive or intolerant, or for refractory or persistent disease.<sup>2,3</sup>

### POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of valrubicin. All approvals are provided for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days. Because of the specialized skills required for evaluation and diagnosis of patients treated with valrubicin as well as the monitoring required for adverse events and long-term efficacy, approval requires valrubicin to be prescribed by or in consultation with a physician who specializes in the condition being treated.

**Automation:** None.

### RECOMMENDED AUTHORIZATION CRITERIA

Coverage of valrubicin is recommended in those who meet the following criteria:

#### FDA-Approved Indication

- 1. Bladder Cancer.** Approve for 2 months if the patient meets the following criteria (A, B, and C):
  - A)** Patient is  $\geq 18$  years of age; AND
  - B)** Patient meets one of the following (i, ii, or ii):
    - i.** Patient has Bacillus Calmette-Guerin (BCG)-refractory carcinoma; OR
    - ii.** Patient is intolerant of Bacillus Calmette-Guerin (BCG); OR
    - iii.** According to the prescriber, valrubicin will be used due to a Bacillus Calmette-Guerin (BCG) shortage; AND
  - C)** The medication is prescribed by or in consultation with an oncologist.

11/30/2022

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

**CONDITIONS NOT RECOMMENDED FOR APPROVAL**

Coverage of valrubicin is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

**REFERENCES**

1. Valstar solution [prescribing information]. Malvern, PA: Endo Pharmaceuticals Solutions; October 2019.
2. The NCCN Drugs and Biologics Compendium. © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on November 28, 2022. Search term: valrubicin.
3. The NCCN Bladder Cancer Clinical Practice Guidelines in Oncology (version 2.2022 – May 20, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on November 28, 2022.